Generate Biomedicines (NASDAQ:GENB) Earns Overweight Rating from Analysts at Piper Sandler

Piper Sandler initiated coverage on shares of Generate Biomedicines (NASDAQ:GENB) in a research note issued to investors on Tuesday, MarketBeat.com reports. The brokerage issued an overweight rating and a $24.00 price target on the stock.

Several other analysts have also recently issued reports on GENB. The Goldman Sachs Group initiated coverage on shares of Generate Biomedicines in a research note on Tuesday. They set a “buy” rating and a $26.00 price objective for the company. Wall Street Zen upgraded Generate Biomedicines to a “hold” rating in a report on Saturday, March 14th. Guggenheim started coverage on Generate Biomedicines in a research report on Tuesday. They issued a “buy” rating and a $30.00 price target for the company. Cantor Fitzgerald initiated coverage on Generate Biomedicines in a research report on Tuesday. They set an “overweight” rating on the stock. Finally, Morgan Stanley assumed coverage on Generate Biomedicines in a research note on Tuesday. They set an “overweight” rating and a $20.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $25.00.

Generate Biomedicines Trading Up 8.6%

NASDAQ:GENB opened at $12.85 on Tuesday. Generate Biomedicines has a twelve month low of $11.00 and a twelve month high of $15.32.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.